Drugs / Yohimbine
Yohimbine
also known as
Yohimbine hydrochloride · NSC-19509 · Prowess plain · Yocon · yohimbine HCl · Yohimbinum
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06430580 | Sep 2024 → Sep 2026 expected | cannabis dependence | Florida State University | Recruiting | No outcome recorded |
| Phase 0 | NCT04346394 | May 2021 → Aug 2023 | Parkinson disease | Nathaniel M. Robbins | Withdrawn | No outcome recorded |
| Phase 0 | NCT02963181 | Mar 2018 → May 2019 | autonomic nervous system disorder, hypertensive disorder, orthostatic hypotension | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Terminated | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03670212 | Jan → Oct 2016 | — | Wayne State University | Completed | No outcome recorded |
| Phase 1 | NCT00223691 | Mar 2002 → Jan 2017 | autonomic nervous system disorder, orthostatic hypotension | Vanderbilt University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03015246 | Dec 2016 → Jun 2020 | heroin dependence | Wayne State University | Completed | No outcome recorded |
| Phase 1/2 | NCT00217048 | Jun → Oct 2005 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04231708 | Oct 2026 → Dec 2028 expected | substance-related disorder | Wayne State University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04180969 | Apr 2023 | — | Wayne State University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01031979 | Dec 2010 → Apr 2015 | post-traumatic stress disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT00605904 | Jan 2008 → Sep 2010 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2 | NCT00535002 | Sep 2007 → Aug 2012 | cocaine dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT00078715 | Mar 2004 → Aug 2009 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00958880 | Mar 2009 → Jan 2013 | social phobia | Southern Methodist University | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06018727 | Jul 2024 → Jul 2025 | borderline personality disorder | University of North Carolina, Chapel Hill | Withdrawn | No outcome recorded |
| Phase 4 | NCT00814047 | — | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT02470026 | Jun 2014 → Nov 2017 | major depressive disorder | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT02541071 | Nov 2013 → Oct 2014 | — | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT01621620 | Aug 2012 → Aug 2013 | — | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03154567 Comparator | Nov 2017 → Oct 2023 | substance abuse | Wayne State University | Completed | No outcome recorded |
| Phase 1 | NCT00748059 Background | Dec 1996 → Dec 2020 | autonomic nervous system disorder, disorder of catecholamine synthesis, orthostatic hypotension | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02243709 Comparator | Sep 2014 → Dec 2021 | alcohol-related disorders | Brown University | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04181515 Comparator | Apr 2023 | opiate dependence | Wayne State University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01593215 Comparator | May 2012 → Oct 2014 | type 2 diabetes mellitus | Anders Rosengren, MD PhD | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04359147 Comparator | Nov 2019 → Dec 2021 | — | Charite University, Berlin, Germany | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yohimbine | “oral medications called yohimbine and hydrocortisone that will be used to study stress responses.” NCT03015246 ↗21“Yohimbine 20 mg capsule will be administered orally.” NCT06018727 ↗ “a single oral yohimbine administration (32.4 mg)” PMID 37369125 ↗ Jul 2023 |
| Known as | NSC-19509 | ChEMBL registry synonym — accepted as the source's own label CHEMBL15245 ↗ |
| Known as | Prowess plain | ChEMBL registry synonym — accepted as the source's own label CHEMBL15245 ↗ |
| Known as | Yocon | ChEMBL registry synonym — accepted as the source's own label CHEMBL15245 ↗ |
| Known as | yohimbine HCl | “Adults (n = 40) with a DSM-IV diagnosis of social anxiety disorder were randomized to placebo or yohimbine HCl (10.8 mg) 1 hour before each of four exposure sessions.” PMID 24237691 ↗ Oct 2013 |
| Known as | Yohimbine hydrochloride | “The specific aim of this study is to assess the efficacy of a single dose of intravenous yohimbine hydrochloride (0.125 mg/kg given over 3 minutes) compared with placebo” NCT00078715 ↗ |
| Known as | Yohimbinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL15245 ↗ |
| Action | Inhibit | “the α-2 adrenergic antagonist yohimbine” PMID 20837887 ↗ Sep 2010 |
| Modality | Small molecule | — CHEMBL15245 ↗ |
| Route | Intravenous | “double-blind crossover administration of either intravenous yohimbine or saline solution during REM sleep” NCT00078715 ↗ |